Headlines about Ra Pharmaceuticals (NASDAQ:RARX) have trended somewhat negative this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Ra Pharmaceuticals earned a media sentiment score of -0.04 on Accern’s scale. Accern also assigned news articles about the company an impact score of 47.8182522898191 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Several equities analysts have recently weighed in on the stock. Zacks Investment Research raised shares of Ra Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, September 19th. Jefferies Group set a $25.00 target price on shares of Ra Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, August 25th. Royal Bank Of Canada assumed coverage on shares of Ra Pharmaceuticals in a research report on Thursday, September 14th. They set an “outperform” rating and a $21.00 price target for the company. BMO Capital Markets reiterated an “outperform” rating and set a $34.00 price target (up from $31.00) on shares of Ra Pharmaceuticals in a research report on Monday. Finally, Credit Suisse Group lifted their price objective on shares of Ra Pharmaceuticals from $19.00 to $23.00 and gave the company an “outperform” rating in a report on Friday, November 10th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $23.80.
Ra Pharmaceuticals (RARX) traded down $5.31 during midday trading on Monday, reaching $8.92. 2,396,401 shares of the company’s stock traded hands, compared to its average volume of 127,338. Ra Pharmaceuticals has a 12 month low of $8.45 and a 12 month high of $27.84.
Ra Pharmaceuticals (NASDAQ:RARX) last issued its quarterly earnings data on Thursday, November 9th. The company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.06). equities analysts forecast that Ra Pharmaceuticals will post -2.46 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This story was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another website, it was illegally copied and reposted in violation of international trademark and copyright legislation. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2017/12/04/ra-pharmctl-rarx-earning-somewhat-negative-press-coverage-report-shows.html.
About Ra Pharmaceuticals
Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.
Receive News & Ratings for Ra Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.